Diabetes: “Strong supply tensions” of drugs, recognizes the Health Products Agency

Two drugs are particularly affected: Ozempic (semaglutide) and Trulicity (dulaglutide). “They are indicated in the treatment of poorly controlled type 2 diabetes, in addition to diet and physical activity”, details the Agency. Despite these difficulties of access, the ANSM calls on affected patients to “not to modify (their) treatment without medical advice”. “Talk to your doctor who will prescribe an alternative if necessary.”